Technology Holding, LLC — Department of Defense SBIR Phase I: CBD192-007

Technology Holding, LLC — SBIR Phase I award from Department of Defense.

Amount
$167,499
Agency
Department of Defense · Office for Chemical and Biological Defense
Program / Phase
SBIR · Phase I
Topic
CBD192-007
Solicitation
19.2
NAICS
Place of performance
UT
Period
2020-04-10 → 2020-10-10

Description

The threat of organophosphate (OP) chemical warfare agents (CWA) to United States military personnel is a persistent problem due to the relative ease of manufacturing chemical threats compared to nuclear and biological agents. Human butyrylcholinesterase (BChE) has been identified as a probable bio-scavenger of OP CWAs that could be used to protect individuals that could be exposed to OP CWAs. The goal of this project is to generate a mammalian cell line capable of expressing human BChE in tetrameric form with appropriate human glycosylation patterns . To achieve this goal we will utilize a triple pronged approach with multiple cell lines currently used to produce human therapeutic proteins. Each approach will be evaluated to determine technical and economic applicability to full scale manufacturing.